1. Introduction {#s0005}
===============

In recent years a large number of structural MRI studies have used either voxel-based morphometry (VBM) to look at volumetric differences in gray matter (GM) structures or diffusion tensor imaging (DTI) to assess white matter (WM) microstructure in functional psychiatric disorders. In bipolar I disorder (BD I), alterations in GM volumes have been reported in many studies but there has been little consistency of effect. Thus, two recent meta-analyses have reported significantly *decreased* GM volumes in the temporal and prefrontal cortices ([@bb0010; @bb0005]), while a recent mega-analysis (i.e., an analysis of individual patient data from multiple studies) reported significantly *increased* temporal lobe, right putamen and right lateral ventricular volumes among BD I patients in comparison to controls ([@bb0015]). Several factors contribute to this heterogeneity. First, lithium treatment, past and present, has been associated with relatively preserved brain volumes ([@bb0030; @bb0015; @bb0020; @bb0025]). Second, BD I patients are often treated with antipsychotics in manic episodes, and over the long term, which may influence brain dimensions as in schizophrenia ([@bb0035]). Third, the uncertain cumulative effects of physical illness and poor lifestyle choices may produce acquired brain changes in mature patients with BD I. Finally, case control imaging studies frequently use poorly defined methods to recruit controls, which results in excessive heterogeneity between control samples, well illustrated in meta-analyses ([@bb0040]). Cases and controls should be recruited using very similar methods, which is always difficult in clinical case series.

Reports of white matter abnormalities in mood disorder patients date from the early days of CT and MR imaging. So-called WM hyperintensities were frequently attributed to vascular pathology ([@bb0045]) and were most noticeable in older patients ([@bb0050; @bb0055]) but also described earlier in the disease course ([@bb0060]). More recent studies using quantitative DTI in samples of mature but not elderly patients with BD I ([@bb0065]) have generally described more diffuse differences between cases and controls. As in the case of studies of GM, consistency has been lacking across DTI studies. For example, *decreases* in fractional anisotropy (FA) -- the most frequently used scalar measure of diffusion -- have been reported in regions of the prefrontal cortex (PFC) ([@bb0070]), corpus callosum ([@bb0075]), cingulum ([@bb0080]), uncinate fasciculi ([@bb0085; @bb0090]), superior longitudinal fasciculi ([@bb0095]) and anterior thalamic radiations ([@bb0085; @bb0090]), while in other studies, *increases* in FA have been reported in regions such as the corpus genu ([@bb0100]), PFC ([@bb0105]), precentral gyrus ([@bb0110]) and uncinate fasciculi ([@bb0105]). Variation in findings across studies is potentially due to the confounding factors already described for GM studies above.

Imaging studies have supported the overarching hypothesis that BD I disorder is in some sense a brain disease. Unanswered has been whether the underlying structural differences reflect the consequences of the illness\'s medium term vascular complications and treatment, relate directly to bipolar psychopathology or are part of a more general developmental brain abnormality seen across the affective spectrum. In order to explore this latter hypothesis, we resolved to assess WM and GM structures in a mood stabilizer- and antipsychotic-naïve group of euthymic individuals with bipolar disorder early in the disease course (i.e., prior to significant clinical intervention). The group in which this approach is most feasible are euthymic, antipsychotic- and mood stabilizer-naïve individuals with BD II or BD not-otherwise-specified (NOS) recruited from the community (as in epidemiological studies) together with healthy control (HC) participants well matched for age, gender, cognitive ability and recruitment route. The further advantage of such cases is the bridge they provide across the affective spectrum between BD I on the one hand and unipolar disorder on the other. We hypothesized that young adults with BD II/NOS would display reductions in FA across the major white matter tracts previously implicated in mature BD I (e.g., callosal, association and limbic fibers).

2. Methods {#s0010}
==========

2.1. Participants and screening {#s0015}
-------------------------------

Participants were 38 unmedicated individuals with BD II/NOS (NOS = 13) and 37 HC participants, group-matched on age, gender and cognitive ability. Thirty-three participants (16 BD) were recruited and underwent structural imaging protocols in the first phase between 2006 and 2008. The remaining 42 participants (22 BD) were recruited and scanned in a second phase (2011 and 2012). Case and control numbers were balanced across the two recruitment phases. All participants were scanned on the same 3 T Siemens Trio system using the same image acquisition protocols (details below).

In order to ensure homogeneity across control and BD participant groups, all participants were recruited from the same population and via the same recruitment route: advertisements were published in a local paper, placed in the community and within the University of Oxford. All volunteers expressing interest in participating were given complete details of the study protocols and invited to attend a screening session. Given the difficulty in recruiting our patient population (i.e., unmedicated individuals with BD II/NOS), individuals previously identified as at-risk for BD (or already meeting full DSM-IV criteria) who had previously participated in other research studies at the University of Oxford\'s Department of Psychiatry (who had also consented to be contacted about future studies) were sent information about the study protocols and invited to take part in the present study via e-mail. Both recruitment methods (advertisement, referrals from other studies) were used to recruit healthy controls and participants with BD II/NOS, in order to ensure the same recruitment route across studies. Following complete description of the study\'s procedures, all participants provided written informed consent. The study protocols were approved by the National Health Service Research Ethics Committee.

All participants were screened using the Mini-International Neuropsychiatric Interview (MINI) ([@bb0115]). This identified the formal criteria for the diagnosis of bipolar disorder for participants in the BD II/NOS group. HC participants were excluded for: (1) any history of head injury or neurological condition; (2) other contraindication to scanning; (3) current or previous use of psychotropic medication; and (4) current or past psychiatric disorder, including substance use and depression, as assessed using the MINI. Exclusion criteria for BD II/NOS participants were: (1) any history of head injury or neurological condition; (2) other contraindication to scanning; (3) current major depressive, manic or hypomanic episodes at the time of scanning; (4) any current psychotropic medication; (5) any past treatment with an antipsychotic or mood stabilizer (e.g., lithium, anticonvulsants); and (6) any current psychiatric disorder (with the exception of BD and anxiety disorders).

All of the thirty-eight BD II/NOS participants had a history of one or more hypomanic episodes as defined using the MINI. Out of the thirty-eight BD II/NOS participants, 25 participants (10 from phase 1) also had a history of one or more major depressive episodes, and therefore met the criteria for BD II. The remaining 13 BD participants (six from phase 1) were classified as NOS. Among the BD II/NOS participants, four met the criteria for past alcohol abuse, two met the criteria for past marijuana abuse and one met the criteria for past codeine abuse and past anorexia. None of the BD II/NOS or HC participants met the criteria for a current substance or alcohol use disorder. Two of the BD II/NOS participants reported a family history of bipolar disorder. Three of the participants in the BD II/NOS group had received previous SSRI treatment, and all had been medication-free for a minimum of three months prior to scanning.

In addition to the MINI, participants completed psychometric assessments of cognitive ability (phase one: Wechsler Abbreviated Scale of Intelligence (WASI) ([@bb0120]); phase two: Raven\'s Matrices ([@bb0125])), current depressive symptoms (Hamilton Depression Rating Scale (HAM-D) ([@bb0130])), lifetime and current bipolar symptoms (Mood Disorders Questionnaire (MDQ) ([@bb0135]); Young Mania Rating Scale (YMRS) ([@bb0140])), impulsivity (Barratt Impulsiveness Scale (BIS-11) ([@bb0145])), and state and trait affect (Positive and Negative Affect Scales (PANAS) ([@bb0150])). Cases and controls were matched on cognitive ability (raw data not shown).

2.2. Image acquisition {#s0020}
----------------------

All data were acquired using the same 3 T Siemens Trio system (Siemens Medical Systems, Erlangen) at the Oxford Centre for Clinical Magnetic Resonance Research, using a protocol consisting of an axial T1-weighted 3D structural (TR = 2040 ms; TE = 4.7 ms, TI = 900 ms, flip angle = 8°; 1 mm isotropic voxels; acquisition time = 5 min 56 s), and an axial multi-slice diffusion weighted EPI (TR = 9300 ms; TE = 94 ms; B values = 0, 1000 s/mm^2^; bandwidth = 1628 Hz/px; directions = 60 \[+ 0\]; averages = 3; 2.5 mm isotropic voxels; no. slices = 50 (whole brain); acquisition time: 21 min 2 s).

2.3. Statistical analyses {#s0025}
-------------------------

### 2.3.1. Demographic and clinical characteristics {#s0030}

The demographic and clinical characteristics of participants in the BD II/NOS and HC groups were analyzed using *χ*^2^ (e.g., gender, handedness) and one-way analysis of variance (ANOVA) analyses, as appropriate.

### 2.3.2. Global WM, GM and CSF volumes {#s0035}

Individual participant T1-weighted images were brain-extracted ([@bb0155]) and whole-brain segmented into GM, WM and CSF following bias field correction using FMRIB\'s automated segmentation tool, FAST ([@bb0160]). Total GM, WM and CSF volumes were calculated for each participant by summing the partial volume estimates in each tissue class, then expressing as a percentage of total brain volume (i.e., the sum of GM, WM and CSF volumes).

### 2.3.3. Gray matter: Voxel-based morphometry (VBM) {#s0125}

Whole-brain GM was analyzed using FSL-VBM as has been described previously ([@bb0165]). The analysis was conducted in the standard way: A study-specific GM template was created by segmenting individual images into GM, WM and CSF, affine registering to the GM ICBM-152 template and averaging the images to form the template. Individual participant images were then non-linearly registered to the study-specific template, and each voxel divided by the Jacobian of the warp field in order to compensate for any expansion/contraction caused by the non-linear registration. All images were smoothed using FSL-VBM\'s default 3 mm Gaussian kernel (\~ 7 mm full width half maximum; FWHM). This kernel size was selected in order to maximize sensitivity to volumetric changes in small structures (e.g., thalamus, hippocampus, anterior cingulate) ([@bb0170]). Between-group comparisons of whole-brain GM data were conducted using permutation-based non-parametric testing ([@bb0175]) while controlling for phase. No other covariates were included. Whole-brain comparisons were corrected for multiple comparisons across space (p \< .05) using Threshold-Free Cluster Enhancement (TFCE; [@bb0180]).

### 2.3.4. White matter microstructures: Tract-based spatial statistics (TBSS) {#s0040}

DTI data were analyzed using TBSS ([@bb0185]). For each participant, three separate image acquisitions were combined and averaged, then brain extracted and corrected for eddy current distortions and head movements prior to undergoing dti_fit to calculate FA (a scalar index of diffusion where 0 indicates completely isotropic diffusion and 1 indicates completely anisotropic diffusion), MD (a scalar index of the total magnitude of diffusion irrespective of direction), parallel (the dominant (major) direction of diffusion; assumed to represent diffusion in the direction of the fiber tract) and perpendicular (the average of the two orthogonal minor directions of diffusion; assumed to represent diffusion perpendicular to the fiber tract) diffusion values. Diffusion data were aligned to common space using nonlinear registration. Individual participant aligned FA, MD and parallel and perpendicular diffusion data were then projected onto the mean FA skeleton in order to obtain voxel-wise comparisons. Between-group comparisons of whole-brain FA, MD, parallel and perpendicular diffusion data were conducted using permutation-based non-parametric testing ([@bb0175]) and were corrected for multiple comparisons across space (p \< .05) using TFCE ([@bb0180]) while controlling for phase. In order to confirm our primary findings and to explore any possible interactions between study phase and diagnostic group, post-hoc comparisons of regional FA between HC and BD II/NOS participants were conducted.

#### 2.3.4.1. Mean whole-brain FA, MD, parallel and perpendicular diffusion values {#s0045}

For each participant, average whole-brain FA, MD, parallel and perpendicular diffusion values (i.e., mean across the entire skeleton) were calculated using fslstats and entered into SPSS. Between-group comparisons were then conducted using ANOVAs.

#### 2.3.4.2. Medication effects {#s0050}

Targeted region-of-interest (ROI) analyses were conducted to test for the effects of past SSRI treatment on early versus late developing white matter tracts (i.e., the splenium and uncinate fasciculus, respectively). Masks were defined using the ICBM-DTI white-matter labels and JHU white-matter tractography atlases and thresholded using the mean FA skeleton. Individual ROI values were converted to Z-scores and analyzed using multivariate analyses of variance.

3. Results {#s0055}
==========

3.1. Demographic and clinical characteristics {#s0060}
---------------------------------------------

Results of between-group comparisons are shown in [Table 1](#t0005){ref-type="table"}. No significant differences in gender, handedness, age and PANAS positive affect (state and trait) were observed between participants with BD II/NOS, in comparison to HC participants. As expected, BD II/NOS participants scored significantly higher than HC participants on measures of impulsivity, experience of manic symptoms/hypomania (i.e., the MDQ), current depressive affect, state and trait negative affect, and current manic symptoms. However, consistent with previous findings ([@bb0190]), depression and mania scores were low among euthymic participants with BD II/NOS (HAM-D = 6.1; YMRS = 1.8), so all participants were euthymic at the time of scanning.

3.2. Global GM, WM, CSF volumes and VBM {#s0065}
---------------------------------------

No significant differences in global GM, WM and CSF volumes were found between BD II/NOS and HC participants ([Table 1](#t0005){ref-type="table"}). The study had sufficient power to detect a difference of 2.25%, 3.25% and 5.50% for WM, GM and CSF volumes, respectively (alpha = 0.05; beta = 0.80) ([@bb0195]). There were no significant between-group differences in voxel-based GM morphometry.

3.3. Tract-based spatial statistics (TBSS) {#s0070}
------------------------------------------

### 3.3.1. BD II/NOS vs. HCs {#s0075}

Findings from whole-brain comparisons of FA, MD and perpendicular diffusion are shown in [Fig. 1](#f0005){ref-type="fig"}. Significant widespread reductions in FA, accompanied by increases in MD and perpendicular diffusivity, were observed among BD participants across the mean skeleton including regions of the genu, body, splenium, forceps major and minor, bilateral cingula, anterior thalamic radiations, external capsules, inferior fronto-occipital fasciculi, inferior and superior longitudinal fasciculi, uncinate fasciculi and brainstem. No significant differences in parallel diffusion were observed between HC and BD II/NOS participants. Across participants, there was no significant effect of study phase on whole-brain FA, MD, parallel or perpendicular diffusion values. Post-hoc comparisons of regional FA revealed no significant main effects of study phase or interaction effects between study phase and group (p \> .05).

### 3.3.2. Mean whole-brain FA, MD, parallel and perpendicular diffusion values {#s0080}

Given the relatively diffuse nature of white matter alterations observed (i.e., alterations within regions of almost all of the major cortical white matter tracts), we calculated the mean FA, MD, parallel and perpendicular diffusion values across the skeleton as a whole, in order to test the hypothesis of gross alterations in diffusion irrespective of specific anatomical loci (e.g., as might result from artifacts such as excess motion within the patient group). There were no significant between-group differences in FA, MD, parallel or perpendicular diffusion values when averaged across the entire skeleton (F\'s \< 1; p\'s \> .35) between HC and BD II/NOS participants.

### 3.3.3. Subtype analyses {#s0085}

Findings from whole-brain comparisons of FA between participants with BD II vs. HC participants and BD NOS vs. HC participants are shown in [Fig. 2](#f0010){ref-type="fig"}. In comparison to HCs, both BD II and NOS groups had significant widespread reductions across the mean FA skeleton, including regions of the genu, body, splenium, forceps major and minor, bilateral anterior thalamic radiations, external capsules, inferior fronto-occipital fasciculi, inferior and superior longitudinal fasciculi, uncinate fasciculi and brainstem.

Whole-brain increases in MD and perpendicular diffusion across the mean skeleton were observed among BD NOS participants across regions of genu, body, splenium, forceps major and minor, bilateral anterior thalamic radiations, cingula, external capsules, inferior fronto-occipital fasciculi, inferior and superior longitudinal fasciculi and uncinate fasciculi. Exploratory analyses using a less stringent threshold (p \< .06, TFCE-corrected) revealed comparable increases for BD II participants versus HCs in perpendicular diffusion across the mean skeleton, including regions of genu, body, splenium, major and minor forceps, right cingulum, bilateral anterior thalamic radiations, external capsules, inferior fronto-occipital fasciculi, inferior and superior longitudinal fasciculi and uncinate fasciculi.

No significant differences in whole-brain FA, MD, parallel or perpendicular diffusion values were observed between participants with BD II versus those with BD NOS.

### 3.3.4. Medication effects: ROI analyses {#s0090}

In comparison to HC participants, participants with BD II/NOS had significant reductions in FA within the splenium (F = 13.23, p = .001) and uncinate fasciculus (left: F = 6.99, p = .010; right: F = 5.91, p = .018) ROIs. After removing the BD II/NOS participants with previous short-term exposure to SSRIs (n = 3), these effects remained (F\'s ≥ 5.98, p\'s ≤ .017). There were no significant differences between BD II/NOS participants with and without previous exposure to SSRIs (F\'s ≤ .31, p\'s ≥ .58).

4. Discussion {#s0095}
=============

To our knowledge, GM and WM structures have not been assessed previously in an adequately powered study of unmedicated individuals with BD II or BD NOS. There were no differences in voxel-based GM morphometry, global WM, GM or CSF volumes between groups despite sample sizes sufficient to detect differences at previously reported levels ([@bb0200]). In contrast, we found significant widespread differences in WM, as indexed by decreased FA and increased MD and perpendicular diffusion, among euthymic, antipsychotic- and mood stabilizer-naïve individuals with BD II/NOS compared with controls. The reductions observed were more profound and more widespread than those typically observed hitherto within a single study of BD I or BD II disorder.

4.1. Gray matter {#s0100}
----------------

The absence of any GM abnormalities among individuals with BD II/NOS contrasts with previous reports of significant decreases in GM volumes, whose location varied across studies, among individuals with BD II ([@bb0205; @bb0210]). The likely explanation is the relatively young age of our participants (mean age = 20.9 years) in comparison to previous studies (i.e., 35.2 years ([@bb0205]); 40.8 years ([@bb0210])). While some evidence of age-related reductions in GM volumes in BD I already exists (e.g., [@bb0215; @bb0015]) very little is currently known about the temporal trajectory in the size of GM structures in BD I or II (reviewed in [@bb0005]). Given the relatively large size of our sample, and our recruitment of cases and controls from the same population, the absence of a GM effect provides a strong negative finding. It implies that GM reductions in older samples are acquired as a consequence of illness course. This is compatible with the very limited prospective data available for BD I ([@bb0220]). Exploring the impact of successful treatment and the relationship between GM changes and cognitive impairment is of obvious clinical relevance for future work ([@bb0225]).

4.2. White matter {#s0105}
-----------------

The reductions in FA encompassed projection, association, callosal and limbic system fibers, just as reported previously in some studies for mature BD I cases (e.g., [@bb0085; @bb0090; @bb0075]). Although the FA reductions were widespread there was no global difference between groups, suggesting some degree of specificity. Our findings are also consistent with previous reports of reduced FA in callosal, projection, and association fibers among mature, medicated individuals with BD II ([@bb0235; @bb0230]), and with findings from the two previous small scale published studies of antipsychotic- and mood stabilizer-naïve adolescents during first-episode mania ([@bb0240]) and manic psychosis ([@bb0245]) which also reported relatively large reductions in FA. Nevertheless, previous DTI and VBM studies have reported a range of semi-conflicting findings (see [Introduction](#s0005){ref-type="sec"}) with respect to WM and GM structures in BD, and the effects of medication have been identified as a possible confound in this literature ([@bb0030]). Preclinical data increasingly suggest ameliorative/protective effects of lithium (frequently used to treat patients with BD over the long-term) on WM tissue; e.g., lithium has been shown to increase remyelination ([@bb0250]). As such, our exclusion of participants with previous exposure to lithium may account for the diffuse nature of the observed reductions in FA. This interpretation is further supported by two recent reports of attenuated FA reductions among lithium-treated patients with BD, in comparison to their non-lithium-treated counterparts ([@bb0255; @bb0260]). Thus, our study may show more clear-cut differences because we controlled for the confounding factors which have influenced the interpretation of the earlier studies.

Although often considered a less severe form of BD than the paradigm illness, the growing research base suggests comparable levels of impairment across both BD I and II ([@bb0265; @bb0270]). The prevalence of the two conditions is approximately equal and BD NOS doubles the total rate to 4--5% of the population ([@bb0280; @bb0275]). Only a small number of studies have previously attempted to characterize the neurostructural correlates of bipolar II disorder (BD II) ([@bb0205; @bb0235; @bb0230; @bb0210]) using VBM or DTI, or to study cases never treated with antipsychotics or mood stabilizers ([@bb0240; @bb0245]). The two recent studies reporting alterations in WM in BD II showed heterogeneous effects and could not control for the possible confounding effects of medication exposure or duration of illness ([@bb0235; @bb0230]). Nevertheless, using a somewhat different scalar measure of diffusion (apparent diffusion coefficient; ADC), [@bb0235] reported increased diffusivity among individuals with BD II in comparison with both controls and BD I participants across multiple tracts encompassing temporal and frontal regions ([@bb0235]). Thus, it is possible that increases in diffusivity may be present across both medicated and unmedicated individuals with BD II.

The BD NOS group remains poorly characterized both clinically and neurobiologically but severity of co-morbidity appears to be less than BD I and BD II ([@bb0285]). Given the small number of NOS participants included in this study (n = 13) these findings should be interpreted cautiously and require replication in a larger sample.

Three participants with BD II/NOS had previously received short-term SSRI therapy, although all had been medication free for at least three months prior to scanning. After removing these participants with past SSRI treatment, reductions in FA within early and late developing tracts (i.e., the splenium and uncinate fasciculus ([@bb0295])) remained significant in the BD II/NOS group, in comparison with control participants. No significant between-group differences in FA were observed between BD II/NOS participants with and without previous exposure to SSRIs.

4.3. Limitations {#s0110}
----------------

To our knowledge, this is the largest DTI study conducted in antipsychotic- and mood stabilizer-naïve individuals with BD, the largest DTI study of individuals with BD II and the first DTI study of individuals with BD NOS. Our image acquisition protocols and data analysis have been well-validated previously ([@bb0185]) and are consistent with previous studies in mature samples of BD I patients ([@bb0305]). Its advantage in controlling for confounds present in most other studies has been described.

These strengths, however, are tempered by the fact that these are not patients as found in clinic samples. While participants from both groups (healthy controls and participants with BD II/NOS) were recruited from the same population (the University of Oxford and surrounding general community) and using closely similar methods, we are not able to report the total number of participants screened and define a true epidemiological sample. Participants were recruited and screened over a number of years and many were first identified as part of separate studies and then referred to this study (see [Methods](#s0010){ref-type="sec"}). They meet the criteria for DSM-IV diagnoses and may map well onto populations also discovered at random in epidemiological samples; however how they relate specifically to treatment-seeking individuals with BD (e.g., with respect to long-term outcome) remains unclear. It is therefore critical that Angst has demonstrated in his seminal prospective studies that cases recruited from the general population who meet the criteria for DSM-IV BD in late adolescence have important long-term morbidity ([@bb0310]). Caution should nonetheless be taken when interpreting these findings with respect to mature patients with BD.

The meaning of reduced FA values (and increased MD) remains to be discovered. At the microstructural level, changes in myelination, straightening of fiber orientation and increased fiber density occur in development and may dominate FA measures in normal brains. While most individuals show increases in FA, a small percentage show decreases over time in the relevant adolescent age group ([@bb0355]). Diffusion tensor imaging may nonetheless be subject to other macrostructural factors like WM volume (which was not different between our groups on VBM) and aberrant mixing of tracts of different fiber orientations, which we cannot entirely exclude. However, the corpus callosum is composed mainly of uniformly oriented fibers ([@bb0360]) so FA values derived from this region are unlikely to be influenced by the presence of crossing fibers. In fact we found reductions in FA in the corpus genu, body and splenium.

Potential artifacts also have to be excluded. We did not employ cardiac gating during diffusion-weighted image acquisition. Intra-individual comparisons of diffusion data obtained with and without cardiac gating demonstrate convincing effects of cardiac pulsation on DTI data ([@bb0385; @bb0390]). However, despite such intra-individual effects, research suggests very minimal effects of cardiac pulsation on FA and MD in group studies ([@bb0385]) and previous studies suggest no differences in pulse or blood pressure between control participants and participants with a bipolar phenotype (some of whom already meet the criteria for BD II/NOS) recruited from the same population as the present study ([@bb0395]). There were also no significant between-group differences in average FA across the entire FA skeleton (as might occur due to excess motion in the patient group).

4.4. Implications {#s0115}
-----------------

The diffuse reduction in FA observed here occurred in a notably young patient sample and was accompanied by increases in perpendicular -- but not parallel -- diffusion values, suggesting decreased fiber coherence or myelination ([@bb0290]) in BD II/NOS. It is consistent with the hypothesis that the abnormality is neurodevelopmental and not acquired as a result of medication or illness course ([@bb0245]). FA increases during adolescence as shown by the cross-sectional study of healthy subjects and this occurs at different rates in different brain structures; thus, the splenium stabilizes much earlier (by age 15 years) than the uncinate fasciculus which is probably still changing at age 30 ([@bb0295]). Our findings show effects in both. In the case of the splenium, the age of our subjects (mean age = 20.9 years) suggests that development would be complete, and hence implies that the difference in FA would be enduring. This finding complements and probably explains the findings of similar differences in mature patients. Data from healthy twins strongly suggest that FA and MD are under genetic control ([@bb0300]).

The findings generate an important hypothesis --- that diffuse WM abnormalities provide a neurodevelopmental marker of vulnerability to affective disorders including but not limited to BD. The BD II/NOS group is intermediate between BD I and unipolar disorder in relation to phenomenology and anxiety co-morbidity ([@bb0285]). And there is already a convincing study showing very comparable WM effects in 20 year-olds with first episode major depressive disorder (MDD) ([@bb0320]) as well as in mature patients with MDD ([@bb0325]); preliminary findings have also suggested a link between WM abnormalities in MDD and generalized anxiety disorder ([@bb0335; @bb0330; @bb0325]). A small study of at risk adolescents with a family history of mood disorder showed the same effect ([@bb0340]): other studies in MDD suggest that treatment resistance may be associated with lower FA ([@bb0345]) while resilience to MDD may be related to higher FA measures ([@bb0350]). Future studies should assess the relationship between WM alterations and effective treatment to determine whether FA might be a useful biomarker for stratification in clinical trials.

Alterations in WM microstructural tissues are relatively common across psychiatric disorders, and are therefore implicated in the source pathophysiology of a range of disorders including -- but not limited to -- BD, attention deficit/hyperactivity disorder (ADHD), schizophrenia and impulse control disorders ([@bb0375; @bb0365; @bb0065; @bb0370; @bb0380]). Thus, alterations in FA, MD and other indices of WM microstructure may be a very general marker of developmental abnormality with the potential for behavioral pathology, rather than a specific marker of BD, per se. Higher resolution studies may clarify any specificity that does exist by diagnosis.

5. Conclusion {#s0120}
=============

We found widespread impairments in white matter microstructures prior to antipsychotic or mood stabilizer treatment among individuals with BD II/NOS. Together with limited data from previous studies of unmedicated individuals with BD I ([@bb0245]) and good studies in unipolar disorder, there is now evidence of pathophysiological involvement of WM microstructures across the mood disorder spectrum. White matter development is a key candidate process for understanding the biological basis of mood disorder and its relationship with related anxiety disorders.
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###### 

Demographic, clinical characteristics and mean brain volumes of bipolar II/NOS and healthy control participants.

  -------------------------------------------------------------------------------------------------
                               Healthy controls\   Bipolar II/NOS\
                               (n = 37)            (n = 38)
  ---------------------------- ------------------- ------------------------------------------------
  Study 1                      17 (46)             16 (43)

  Male                         20 (54)             20 (53)

  Right-handed                 34 (92)             36 (95)

                                                   

                               Mean (St. dev.)     Mean (St. dev.)

  Age                          21.2 (2.3)          20.9 (3.1)

  MDQ                          0.1 (.03)           9.5 (1.7)[⁎⁎⁎](#tf0015){ref-type="table-fn"}

  HAM-D                        2.3 (2.3)           6.1 (5.6)[⁎⁎⁎](#tf0015){ref-type="table-fn"}

  YMRS                         0.3 (0.5)           1.8 (2.5)[⁎⁎](#tf0010){ref-type="table-fn"}

  BIS-11                       54.7 (7.0)          69.4 (10.1)[⁎⁎⁎](#tf0015){ref-type="table-fn"}

  PANAS-state                                      

   Positive                    29.7 (6.8)          30.2 (6.8)

   Negative                    11.7 (2.3)          13.6 (3.3)[⁎](#tf0005){ref-type="table-fn"}

  PANAS-trait                                      

   Positive                    33.7 (5.3)          32.1 (6.8)

   Negative                    13.3 (3.1)          20.4 (7.1)[⁎⁎⁎](#tf0015){ref-type="table-fn"}

  Brain volumes (% of total)                       

   Gray matter                 42.8 (1.4)          43.1 (1.4)

   White matter                37.3 (1.7)          37.4 (1.8)

   CSF                         19.9 (1.7)          19.5 (1.4)
  -------------------------------------------------------------------------------------------------

MDQ = Mood Disorders Questionnaire; HAM-D = Hamilton Depression Inventory; YMRS = Young Mania Rating Scale; PANAS = Positive and Negative Affect Scales; CSF = Cerebrospinal Fluid.

p ≤ .005.

p ≤ .001.

p ≤ .0001.
